HIV-associated tuberculosis in the era of highly active antiretroviral therapy

被引:0
|
作者
Jones, JL [1 ]
Hanson, DL [1 ]
Dworkin, MS [1 ]
DeCock, KM [1 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA
关键词
HIV; AIDS; tuberculosis; antiretroviral therapy;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVE: To determine the effect of highly active antiretroviral therapy (HAART) on the risk of tuberculosis (TB) among persons infected with the human immunodeficiency virus (HIV), and to examine trends in TB. METHODS: For the risk factor analysis, we examined data from the Adult/Adolescent Spectrum of HN Disease (ASD) project from January 1996 through June 1998. ASD is an observational cohort study conducted in over 100 clinics and hospitals in 11 US cities. Poisson regression was used to model the incidence of TB while controlling for HIV-exposure mode, race, country of birth, CD4 count, TB preventive therapy, and half-year of diagnosis. We also examined trends in TB incidence January 1992 to June 1998. RESULTS: During the risk factor analysis period, 80 cases of TB occurred in 16 032 person-years (5.0 cases/ 1000 person-years). In multivariate analysis, the risk of TB was much lower among persons prescribed HAART (RR = 0.2, 95% CI 0.1-0.5, P< 0.001), and also lower among persons prescribed other antiretroviral therapy (RR = 0.6, 95% CI 0.4-1.0, P = 0.05), than the risk in persons not prescribed antiretroviral therapy In addition, TB rates declined from January 1992 to June 1998 (P < 0.001). CONCLUSION: Widespread use of HAART reduced the risk for TB and may help bring about further declines in TB among persons infected with HIV.
引用
收藏
页码:1026 / 1031
页数:6
相关论文
共 50 条
  • [1] HIV-associated tuberculosis in the era of highly active antiretroviral therapy
    Sackoff, J
    Bernard, MA
    Adams, L
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2001, 5 (05) : 489 - 489
  • [2] Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy
    Dheda, K
    Lampe, FC
    Johnson, MA
    Lipman, MC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (09): : 1670 - 1676
  • [3] HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy
    Tumbarello, M
    Tacconelli, E
    Donati, KD
    Cauda, R
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (02): : 208 - 209
  • [4] HIV-associated dementia in the era of highly active antiretroviral therapy (HAART)
    Xia, Chenglai
    Luo, Dixian
    Yu, Xiaoling
    Jiang, Shibo
    Liu, Shuwen
    [J]. MICROBES AND INFECTION, 2011, 13 (05) : 419 - 425
  • [5] HIV-associated painful neuropathy in the era of highly active antiretroviral therapy
    Schifitto, G
    McDermott, MP
    McArthur, JC
    Marder, K
    Sacktor, N
    Cohen, B
    Epstein, L
    Kieburtz, K
    [J]. ANNALS OF NEUROLOGY, 2003, 54 : S50 - S50
  • [6] Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy
    Cosgrove, CJ
    Abu-Alfa, AK
    Perazella, MA
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2002, 323 (02): : 102 - 106
  • [7] Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy
    Little, RF
    Yarchoan, R
    Wilson, WH
    [J]. CURRENT OPINION IN ONCOLOGY, 2000, 12 (05) : 438 - 444
  • [8] Outcome of HIV associated tuberculosis in the era of highly active antiretroviral therapy (HAART)
    Dheda, K
    Lampe, F
    Lipman, M
    Johnson, M
    [J]. THORAX, 2002, 57
  • [9] HIV-associated community-acquired pneumonia in the highly active antiretroviral therapy era
    Viale, P
    Scudeller, L
    Signorini, L
    Cadeo, B
    Petrosillo, N
    Pagani, L
    Carosi, G
    [J]. AIDS, 2002, 16 (17) : 2361 - 2362
  • [10] Discontinuation of prophylaxis for HIV-associated opportunistic infections in the era of highly active antiretroviral therapy
    Hermsen, ED
    Wynn, HE
    McNabb, J
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (03) : 245 - 256